LAEKNA-B

Laekna Inc. rose sharply today, closing at HKD 7.800, up 6.70% from the previous close, with a turnover of HKD 15.1 million and a turnover rate of 0.44%. The stock gained momentum in the afternoon session, hitting an intraday high of HKD 7.850 after a low of HKD 7.330, forming a low-open high-go pattern. Q3 2025 revenue surged 24,927.84% YoY to HKD 55.9 million, but net loss narrowed only 11.11% to HKD 54.5 million, with EPS at -HKD 0.1353. Despite the losses, the stock price remains well below its 52-week high, and the market's focus on its pipeline progress drove the rally. However, the net profit margin remains deeply negative at -97.53%, underscoring the company's pre-revenue stage.

来凯医药今日放量上涨 9.7%，收报 7.37 港元，主因公司披露最高达 5600 万港元的场内股份回购计划，由董事长吕向阳及主要股东等内部人士支持，直接提振市场信心。盘中走势呈探底回升：上午盘一度从 7.13 港元开盘后冲高至 7.45 港元，但随即回落至 6.9 港元日内低点，下午盘逐步回升至收盘高位，全天成交额 4604 万港元，为近期较活跃水平。股价当前仍较 52 周高点 20.9 港元下跌 65%，YTD 跌幅 45.8%，且处于 20 日均线 8.23 港元和 60 日均线 12.64 港元之下，价格位置偏弱。财报方面，Q4 2025 营业收入达 5683 万港元，同比大增超 264 倍，净亏损收窄至 5542 万港元，EPS 亏损 0.14 港元同比改善 15.9%，基本面边际改善。此外，公司近期授予 Vasque Bio LAE118 的大中华区外全球权益，产品管线持续推进。不过，公司仍处于研发阶段尚无商业化产品，且近期高管秘书有人员变动。